ONPH Company Profile and Key Details

Average 10-day trading volume of 7.42 thousand shares is below the 3-month average of 15.33 thousand, indicating normal recent market interest.

The stock is currently mid-range between its 52-week high and low $0.00 and $0.36. With a market capitalization of about $1.41 million, Oncology Pharma Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.13). Key stats such as the average daily volume over the past year has been around 17.55 thousand shares, volume is running light vs its 52-week average. Headquartered in San Francisco, CA, Oncology Pharma Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO George Malesek, the company employs approximately 1 people and listed since October 31, 1994. Oncology Pharma Inc. is a pharmaceutical firm specializing in oncology, dedicated to the development, manufacturing, and commercialization of therapeutic agents.

Oncology Pharma Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.02. This means the shares are trading below this model’s fair value.

Valuation shows Oncology Pharma Inc. trading at a premium to the broader market with a P/E of -734.12.

Our AI price prediction model suggests that Oncology Pharma Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Oncology Pharma Inc. trades at a P/E ratio of -734.12, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.43 trading at moderately above to book value. The P/FCF stands at 3.86, also above market averages.